Acquired Company

AstraZeneca completed the acquisition of Gracell Biotechnologies on February 22, 2024.

Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for cancer treatment in the People's Republic of China. The company is headquartered in Suzhou, China. Show more

BUILDING 12, BLOCK B, SUZHOU, CHINA, 215123, China

BIOTECHNOLOGY

HEALTHCARE

Market Cap

989.9M

52 Wk Range

$306.65 - $629.20

Previous Close

$10.25

Open

$10.25

Volume

N/A

Day Range

$10.25 - $10.25

Enterprise Value

0.00

Cash

1.677B

Avg Qtr Burn

N/A

Insider Ownership

16.39%

Institutional Own.

63.11%

Qtr Updated

09/30/23

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
GC012F Details Multiple myeloma, Cancer	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GC012F Details Autoimmune disease, Systemic lupus erythematosus	Phase 1/2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GC007g Details B-cell acute lymphoblastic leukemia	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.